Search Results for “L3M2 Studienmaterialien: Ethical Procurement and Supply – L3M2 Torrent Prüfung – L3M2 wirkliche Prüfung 🍱 Suchen Sie auf （ www.itzert.com ） nach 《 L3M2 》 und erhalten Sie den kostenlosen Download mühelos 🙁L3M2 Prüfungs-Guide” – Page 11

Ligelizumab for Chronic Spontaneous Urticaria

360

Maurer, M.+, Giménez-Arnau, A. M., Sussman, G., Metz, M., Baker, D. R., Bauer, A., Bernstein, J. A., Brehler, R., Chu, C.-Y., Chung, W.-H., Danilycheva, I., Grattan, C., Hebert, J., Katelaris, C., Makris, M., Meshkova, R., Savic, S., Sinclair, R., Sitz, K., Staubach, P., Wedi, B., Löffler, J., Barve, A., Kobayashi, K., Hua, E., Severin, T., and Janocha, R.: Ligelizumab for chronic spontaneous urticaria. New Engl. J. Med. 2019: 381; 1321-1332. IF: 74.70

o.360

Efficacy and safety of Dupilumab for moderate-to-severe atopic dermatitis: a systematic review for the EAACI biologicals guidelines

411.

Agache, I.⁺, Song, Y., Posso, M., Alonso-Coello, P., Rocha, C., Solà, I., Beltran, J., Akdis, C., Akdis, M., Brockow, K., Chivato, T., del Giacco, S., Eiwegger, T., Eyerich, K., Giménez-Arnau, A., Gutermuth, J., Guttman-Yassky, E., Maurer, M., Ogg, G., Ong, P. Y., O’Mahony, L., Schwarze, J., Werfel, T., Canelo-Aybar, C.*, Palomares, O.*, and Jutel, M.*: Efficacy and safety of Dupilumab for moderate-to-severe atopic dermatitis: a systematic review for the EAACI biologicals guidelines. Allergy 2021: 76; 45-58. IF: 14.71

o.411

473.	Chuamanochan, M., Chiewchanvit, S., Tovanabutra, N., Rujiwetpongstorn, R., Laosakul, K., and Maurer, M.⁺: A case of dengue fever presenting with acute urticaria. Asian Pac. J. Allergy Immunol. 2022: 40; 72-74. IF: 5.00

o.473

239	Maurer, M.+, Staubach, P., Raap, U., Richter-Huhn, G., Baier-Ebert, M., and Chapman-Rothe, N.: ATTENTUS, a German survey of chronic urticaria patients highlightening the burden of disease, unmet needs and real-life clinical practice. Brit. J. Dermatol. 2016: 174; 892-894. IF: 4.70

447.	Spindler, M., Przybylowicz, K., Hawro, M., Weller, K., Reidel, U., Metz, M., Maurer, M., and Hawro, T.⁺: Sleep disturbance in adult dermatological patients: a cross-sectional study on prevalence, burden and associated factors. J. Am. Acad. Dermatol. 2021: 85; 910-922. IF: 15.49

o.447

118	Luckey, U., Maurer, M., Schmidt, T., Lorenz, N., Seebach, B., Metz, M., and Steinbrink, K.+: T cell killing by tolerogenic dendritic cells protects from allergy in mice. J. Clin. Invest. 2011: 121; 3860-3871. IF: 13.06

o.118

195.	Kolkhir, P.⁺, Grad, D. A., Charalampous, P., Cruz Oliveira, C., Mechili, E. A., Unim, B., Pearce, D. A., Maurer, M., Devleesschauwer, B., and Haagsma, J.: An EU task force to assess the burden of rare diseases. Nat. Medicine 2023: 29; 516-517. IF: 58.70

r.195

An international Delphi study on the burden of allergic rhinoconjunctivitis and urticaria and the role of bilastine among current treatment options

536.

Church, M. K.⁺, Canonica, G. W., Kuna, P., Maurer, M., Mösges, R., Novak, Z., Papadopoulos, N. G., Rodriguez del Rio, P., and the Delphi Study Group: An international Delphi study on the burden of allergic rhinoconjunctivitis and urticaria and the role of bilastine among current treatment options. Expert Rev. Clin. Immunol. 2023: 19; 813-820. IF: 3.90

o.536

Ligelizumab improves sleep interference and disease burden in patients with chronic spontaneous urticaria

469.

Giménez-Arnau, A.⁺, Maurer, M., Bernstein, J. A., Staubach, P., Barbier, N., Hua, E., Severin, T., Joubert, Y., Janocha, R., and Balp, M.-M.: Ligelizumab improves sleep interference and disease burden in patients with chronic spontaneous urticaria. Clin. Transl. Allergy 2022: 12; e12121. IF: 4.40

o.469

50.	Church, M. K., Weller, K., Stock, P., and Maurer, M.: Chronic spontaneous urticaria in children: itching for insight. Pediatr. Allergy Immunol. 2011: 22; 1-8. IF: 2.45

Results